VanEck Associates’s CareDx CDNA Stock Holding History

VanEck Associates’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-681	Closed	-$12K	–	1427
2022 Q3	$12K	Buy	+681	New	+$14.6K	﹤0.01%	1332

Other funds holding CDNA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

VanEck Associates's CDNA Position: Q4 2022 in Review

VanEck Associates sold out of CareDx (CDNA) in Q4 2022, closing a stake of 681 shares — an estimated $12K sold.

VanEck Associates first reported a position in CDNA in Q3 2022 and held it in 1 quarter. The position peaked at $12K in Q3 2022. 168 funds tracked by Wall St. Rank hold CDNA as of Q4 2022.

VanEck Associates reported no remaining CareDx position as of Q4 2022 after selling out during the quarter.
VanEck Associates sold 681 CareDx shares in Q4 2022, an estimated $12K.
VanEck Associates first reported a position in CareDx in Q3 2022 and held it in 1 quarter.
VanEck Associates's CareDx position peaked at $12K in Q3 2022.
168 funds tracked by Wall St. Rank held CareDx as of Q4 2022.

Based on VanEck Associates's 13F filing for Q4 2022, filed 8 Feb 2023.